We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis Pharmaceuticals, Inc. (IONS - Free Report) reported fourth-quarter adjusted earnings per share of 81 cents compared with $1.38 per share in the year-ago period.
Adjusted earnings exclude expenses related to the Akcea acquisition and restructured European operations. Including these non-recurring expenses, loss per share was $2.44 per share. The Zacks Consensus Estimate stood at earnings of 24 cents per share.
Ionis reported total revenues of $290 million, down 41.3% year over year due to lower R&D revenues and royalties on Spinraza in the quarter. Sales however beat the Zacks Consensus Estimate of $266 million.
In October 2020, Ionis acquired the remaining stake in Akcea Therapeutics and the latterbecame a wholly owned subsidiary of Ionis. Prior to completing its acquisition of Akcea, Ionis owned approximately 76% of Akcea
This year so far, Ionis’ shares have declined 0.6% against the industry’s increase of 3%.
Quarter in Detail
Ionis has three commercial medicines approved in major global markets, Spinraza, Tegsedi and Waylivra. It has licensed Spinraza to Biogen (BIIB - Free Report) .
Biogen is responsible for commercializing Spinraza, approved for treating spinal muscular atrophy, or SMA, worldwide. Ionis receives royalties from Biogen on Spinraza’s sales. Tegsedi (hereditary TTR amyloidosis, or hATTR) and Waylivra (genetically confirmed familial chylomicronemia syndrome, or FCS) are its own products. While Tegsedi is marketed in both the United States and EU, Waylivra is marketed in European countries.
Ionis earns commercial revenues, primarily royalty payments on net sales of Spinraza and R&D revenues, from partnered medicines. Ionis has collaboration deals with leading drugmakers/biotech companies namely AstraZeneca (AZN - Free Report) , Bayer, Biogen, Glaxo, J&J, Novartis, Pfizer (PFE - Free Report) and Roche for developing and marketing their medicines.
Fourth-quarter revenues comprised commercial revenues of $96 million, down 4% year over year, and R&D revenues of $194 million, down 51% from the year-ago quarter.
Commercial revenues from Spinraza royalties were $75 million, down 7.4% year over year as Biogen reported softer sales of the drug. Product sales from Tegsedi and Waylivra were $19 million, compared with $13 million in the year-ago quarter. License and royalty revenues were $2 million in the quarter compared with $6 million in the year-ago quarter.
Adjusted operating costs declined 5.6% year over year to $187 million in the fourth quarter of 2020.
Pipeline Update
Ionis has six pivotal phase III studies ongoing for four medicines (internal as well as partnered), which include tominersen for Huntington’s disease; tofersen for SOD1-ALS; pelacarsen for cardiovascular disease due to elevated Lp(a) levels and AKCEA-TTR-LRx for TTR amyloidosis and familial chylomicronemia syndrome (FCS). Its partners, Biogen, Roche and Novartis are now engaged in leading global development and commercialization activities related to tofersen, tominersen and pelacarsen, respectively after Ionis developed them in the early stages. Ionis is eligible to receive milestone payments and royalties on sales of these medicines if they are approved. Ionis is developing AKCEA-TTR-LRx on its own. Top-line data from tofersen phase III study is expected in the second half of 2021
Meanwhile, Ionis also has several other candidates in phase II development, which it is developing in partnership with Biogen, Roche or on its own. Ionis is advancing and expanding its wholly-owned pipeline and data from several of these programs is expected in the first half.
Ionis expects to have 12 or more products on the market in 2026.
2021 Guidance
Ionis expects total revenues in 2021 to be more than $600 million while adjusted net loss is expected to be less than $75 million. The Zacks Consensus Estimate for 2021 sales stands at $765.7 million.
Adjusted operating expense are expected to be in the range of $675 million to $725 million as Ionis invests in expanding its wholly-owned pipeline and building its commercial capabilities. Ionis expects R&D expenses to increase approximately 25% to 35% in 2021 compared to last year while SG&A expenses are expected to decrease. Ionis expects R&D revenues to be higher in the second half of the year compared to the first.
Ionis currently carries a Zacks Rank #5 (Strong Sell).
Ionis Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates
Ionis Pharmaceuticals, Inc. (IONS - Free Report) reported fourth-quarter adjusted earnings per share of 81 cents compared with $1.38 per share in the year-ago period.
Adjusted earnings exclude expenses related to the Akcea acquisition and restructured European operations. Including these non-recurring expenses, loss per share was $2.44 per share. The Zacks Consensus Estimate stood at earnings of 24 cents per share.
Ionis reported total revenues of $290 million, down 41.3% year over year due to lower R&D revenues and royalties on Spinraza in the quarter. Sales however beat the Zacks Consensus Estimate of $266 million.
In October 2020, Ionis acquired the remaining stake in Akcea Therapeutics and the latterbecame a wholly owned subsidiary of Ionis. Prior to completing its acquisition of Akcea, Ionis owned approximately 76% of Akcea
This year so far, Ionis’ shares have declined 0.6% against the industry’s increase of 3%.
Quarter in Detail
Ionis has three commercial medicines approved in major global markets, Spinraza, Tegsedi and Waylivra. It has licensed Spinraza to Biogen (BIIB - Free Report) .
Biogen is responsible for commercializing Spinraza, approved for treating spinal muscular atrophy, or SMA, worldwide. Ionis receives royalties from Biogen on Spinraza’s sales. Tegsedi (hereditary TTR amyloidosis, or hATTR) and Waylivra (genetically confirmed familial chylomicronemia syndrome, or FCS) are its own products. While Tegsedi is marketed in both the United States and EU, Waylivra is marketed in European countries.
Ionis earns commercial revenues, primarily royalty payments on net sales of Spinraza and R&D revenues, from partnered medicines. Ionis has collaboration deals with leading drugmakers/biotech companies namely AstraZeneca (AZN - Free Report) , Bayer, Biogen, Glaxo, J&J, Novartis, Pfizer (PFE - Free Report) and Roche for developing and marketing their medicines.
Fourth-quarter revenues comprised commercial revenues of $96 million, down 4% year over year, and R&D revenues of $194 million, down 51% from the year-ago quarter.
Commercial revenues from Spinraza royalties were $75 million, down 7.4% year over year as Biogen reported softer sales of the drug. Product sales from Tegsedi and Waylivra were $19 million, compared with $13 million in the year-ago quarter. License and royalty revenues were $2 million in the quarter compared with $6 million in the year-ago quarter.
Adjusted operating costs declined 5.6% year over year to $187 million in the fourth quarter of 2020.
Pipeline Update
Ionis has six pivotal phase III studies ongoing for four medicines (internal as well as partnered), which include tominersen for Huntington’s disease; tofersen for SOD1-ALS; pelacarsen for cardiovascular disease due to elevated Lp(a) levels and AKCEA-TTR-LRx for TTR amyloidosis and familial chylomicronemia syndrome (FCS). Its partners, Biogen, Roche and Novartis are now engaged in leading global development and commercialization activities related to tofersen, tominersen and pelacarsen, respectively after Ionis developed them in the early stages. Ionis is eligible to receive milestone payments and royalties on sales of these medicines if they are approved. Ionis is developing AKCEA-TTR-LRx on its own. Top-line data from tofersen phase III study is expected in the second half of 2021
Meanwhile, Ionis also has several other candidates in phase II development, which it is developing in partnership with Biogen, Roche or on its own. Ionis is advancing and expanding its wholly-owned pipeline and data from several of these programs is expected in the first half.
Ionis expects to have 12 or more products on the market in 2026.
2021 Guidance
Ionis expects total revenues in 2021 to be more than $600 million while adjusted net loss is expected to be less than $75 million. The Zacks Consensus Estimate for 2021 sales stands at $765.7 million.
Adjusted operating expense are expected to be in the range of $675 million to $725 million as Ionis invests in expanding its wholly-owned pipeline and building its commercial capabilities. Ionis expects R&D expenses to increase approximately 25% to 35% in 2021 compared to last year while SG&A expenses are expected to decrease. Ionis expects R&D revenues to be higher in the second half of the year compared to the first.
Ionis currently carries a Zacks Rank #5 (Strong Sell).
Ionis Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Ionis Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Ionis Pharmaceuticals, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>